WSO - April 2023 - 415

Chen et al.
415
Supplemental material
Supplemental material for this article is available online.
References
1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization
of terminology, definitions and outcome criteria in immune
thrombocytopenic purpura of adults and children: report
from an international working group. Blood 2009; 113:
2386-2393.
2. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of
immune thrombocytopenic purpura in the general practice
research database. Br J Haematol 2009; 145: 235-244.
3. Frederiksen H and Schmidt K. The incidence of idiopathic
thrombocytopenic purpura in adults increases with age. Blood
1999; 94: 909-913.
4. Zufferey A, Kapur R and Semple JW. Pathogenesis and
Therapeutic
Mechanisms in Immune Thrombocytopenia
(ITP). J Clin Med 2017; 6: 16.
5. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory
T-cell changes in patients with idiopathic thrombocytopenic
purpura receiving B cell-depleting therapy with rituximab.
Blood 2008; 112: 1147-1150.
6. Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A
and of the cytokines involved in Th17 cell commitment are
increased in patients with chronic immune thrombocytopenia.
Haematologica 2011; 96: 1560-1564.
7. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell
activity in patients with chronic immune thrombocytopenia
treated with thrombopoietic agents. Blood 2010; 116:
4639-4645.
8. Adelborg K, Kristensen NR, Nørgaard M, et al. Cardiovascular
and bleeding outcomes in a population-based cohort of
patients with chronic immune thrombocytopenia. J Thromb
Haemost 2019; 17: 912-924.
9. Khan NA, McAlister FA, Pilote L, et al. Temporal trends in
stroke incidence in South Asian, Chinese and white patients: a
population based analysis. PLoS ONE 2017; 12: e0175556.
10. Chandan JS, Thomas T, Lee S, et al. The association between
idiopathic thrombocytopenic purpura and cardiovascular disease:
a retrospective cohort study. J Thromb Haemost 2018;
16: 474-480.
11. Enger C, Bennett D, Forssen U, Fogarty PF and McAfee AT.
Comorbidities in patients with persistent or chronic immune
thrombocytopenia. Int J Hematol 2010; 92: 289-295.
12. Nørgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial
thrombotic and venous thromboembolic events in
patients with primary chronic immune thrombocytopenia: a
Scandinavian population-based cohort study. Br J Haematol
2016; 174: 639-642.
13. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic
events among adult patients with primary immune thrombocytopenia
in the United Kingdom general practice research
database. Haematologica 2010; 95: 1167-1175.
14. Jy W, Horstman LL, Arce M and Ahn YS. Clinical significance
of platelet microparticles in autoimmune thrombocytopenias.
J Lab Clin Med 1992; 119: 334-345.
15. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles
in transient ischemic attacks, lacunar infarcts, and
multiinfarct dementias. Thromb Res 1993; 72: 295-304.
16. Ichijo M, Ishibashi S, Ohkubo T, et al. Elevated platelet microparticle
levels after acute ischemic stroke with concurrent idiopathic
thrombocytopenic purpura. J Stroke Cerebrovasc Dis
2014; 23: 587-589.
17. Frelinger AL 3rd, Grace RF, Gerrits AJ, Carmichael SL, Forde
EE and Michelson AD. Platelet function tests, independent of
platelet count, are associated with bleeding severity in ITP.
Blood 2015; 126: 873-879.
18. Guo S, Lin Y, Ma X, et al. Long-term safety and efficacy of
antiplatelet therapy in patients with cerebral infarction with
thrombocytopenia. Clin Appl Thromb Hemost 2021; 27:
1076029620980067.
19. Rørholt M, Ghanima W, Farkas DK and Nørgaard M. Risk of
cardiovascular events and pulmonary hypertension following
splenectomy-a Danish population-based cohort study from
1996-2012. Haematologica 2017; 102: 1333-1341.
International Journal of Stroke, 18(4)
WSO - April 2023

Table of Contents for the Digital Edition of WSO - April 2023
